Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years. Owing to the lack of rapid diagnostics, the disease quickly spreads to other parts of the body, resulting in a poor prognosis and limited treatment options. First-line treatment of metastatic pancreatic cancer is dominated by chemotherapeutic agents such as gemcitabine and Abraxane, with limited efficacy. Tarceva is the only targeted therapy approved for pancreatic cancer. This report presents a detailed analysis of the goals of pancreatic cancer treatment in the locally advanced and metastatic settings. We assess how current therapies perform on key drug attributes and measure the impact of drug attributes on physicians’ prescribing behavior. We also review which unmet needs novel therapies should address to distinguish themselves from their rivals and maximize uptake.


  • What are the treatment drivers and goals for locally advanced and metastatic pancreatic cancer?
  • What are the key influencers of treatment decisions and the hidden opportunities that developers could leverage?
  • How do current therapies, such as Ipsen / Servier’s Onivyde, Roche / Genentech’s Tarceva, and chemotherapy regimens, perform on key clinical drug attributes for this patient population?
  • What are the prevailing areas of unmet need and opportunity in locally advanced and metastatic pancreatic cancer?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European oncologists for a new treatment for first-line metastatic pancreatic cancer?


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2019

Key companies: Eli Lilly, Genentech / Roche, Celgene, Merck, Ipsen / Servier

Key drugs: Gemcitabine, FOLFIRINOX, Capecitabine, Tarceva, Abraxane, Keytruda, Onivyde

Table of contents

  • Detailed, Expanded Analysis (US/EU) Locally Advanced or Metastatic Adenocarcinoma
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Pancreatic Cancer
      • Key Findings: Unmet Need in Pancreatic Cancer and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Pancreatic Cancer Market and Emerging Therapy Insights
        • Opportunity: A New Therapy with Improved Efficacy Attributes
        • Opportunity: A Novel Therapy with an Improved Safety and Tolerability Profile
        • Opportunity: A Novel Agent with Improved Convenience of Administration
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • First-Line Metastatic Pancreatic Cancer Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Ananya Sadhu, Ph.D

Ananya Sadhu, is an analyst with the oncology team at Decision Resources Group with expertise in multiple oncology indications including pancreatic cancer. Prior to joining Decision Resources Group, Dr. Ananya Sadhu was a postdoctoral fellow at National Centre of Biological Sciences, Bangalore, where she studied the role of chromatin architecture in regulating gene expression in breast cancer. Ananya holds a in Molecular Biology from National Institute of Immunology, New Delhi. She also worked as a Scientific Officer with Arvind Remedies Ltd., a pharmaceutical company, where she coordinated various stages of non-clinical / clinical research activities for drug development of a patented polyherbal formulation.

Related Reports

Pancreatic Cancer | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevale...

View Details

Pancreatic Cancer | Landscape & Forecast | Disease Landscape & Forecast

Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation...

View Details

Pancreatic Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key  pancreatic cancer&nb...

View Details